Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Earnings
Lannett raises FY20 adj. revenue view to $530M-$550M from $525M-$545M  16:21
02/05/20
02/05
16:21
02/05/20
16:21
LCI

Lannett

$8.93 /

+0.365 (+4.26%)

FY20 consensus $536.21M.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Lannett reports Q2 adjusted EPS 27c, consensus 27c » 16:20
02/05/20
02/05
16:20
02/05/20
16:20
LCI

Lannett

$8.93 /

+0.365 (+4.26%)

Reports Q2 revenue…

Reports Q2 revenue $136.1M, consensus $128.6M.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a month ago
Hot Stocks
Fly Intel: Pre-market Movers » 09:20
01/13/20
01/13
09:20
01/13/20
09:20
LULU

Lululemon

$234.79 /

-1.14 (-0.48%)

, LCI

Lannett

$8.27 /

+0.03 (+0.36%)

, WCC

Wesco

$58.09 /

-0.425 (-0.73%)

, AXE

Anixter

$98.77 /

-0.02 (-0.02%)

, TERP

TerraForm Power

$15.60 /

+0.085 (+0.55%)

, BEP

Brookfield Renewable

$48.04 /

-0.45 (-0.93%)

, HOME

At Home Group

$5.09 /

-0.095 (-1.83%)

, JILL

J.Jill

$1.38 /

-0.01 (-0.72%)

, ABMD

Abiomed

$188.93 /

+5.2 (+2.83%)

, EXAS

Exact Sciences

$104.60 /

+1 (+0.97%)

, CHKP

Check Point

$112.55 /

+0.83 (+0.74%)

HIGHER: Lululemon (LULU),…

HIGHER: Lululemon (LULU), up 2% after raising its Q4 EPS outlook... Lannett (LCI), up 7% after announcing FDA approval of its Cocaine Hydrochloride Nasal Solution new drug application... Wesco (WCC), up 3% after announcing a definitive merger agreement under which the company will acquire Anixter (AXE) in a transaction valued at approximately $4.5B... TerraForm Power (TERP), up 9% after announcing Brookfield Renewable Partners (BEP) has made a non-binding, all-share proposal to acquire the outstanding Class A common shares of the company, other than the 62% owned by Brookfield Renewable and its affiliates... At Home Group (HOME), up 13% after announcing Q4 sales will be at the higher end of the previously guided range... J.Jill (JILL), up 18% after raising its Q4 EPS view. LOWER: Abiomed (ABMD), down 11% after reporting preliminary Q3 revenue... Exact sciences (EXAS), down 6% after reporting preliminary Q4 revenue .. Check Point (CHKP), down 2% after Morgan Stanley analyst Keith Weiss downgraded shares to Underweight from Equal Weight with a price target of $106, down from $115.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Lannett announces FDA approval of its Cocaine Hydrochloride Nasal Solution NDA » 06:57
01/13/20
01/13
06:57
01/13/20
06:57
LCI

Lannett

$8.27 /

+0.03 (+0.36%)

Lannett announced that…

Lannett announced that the FDA has approved the new drug application, or NDA, submitted under the 505 regulatory pathway, for Cocaine Hydrochloride, or HCl, Nasal Solution 4%, the company's branded local anesthetic product. Numbrino nasal solution is an ester local anesthetic indicated for the introduction of local anesthesia of the mucous membranes for diagnostic procedures and surgeries on or through the nasal cavities of adults. The 505 NDA submission was supported by two Phase III, randomized, double-blind, placebo-controlled, multicenter studies in several hundred patients, as well as a Phase I pharmacokinetic study.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Lannett commences marketing for Venlafaxine ER tablets, Lidocaine solution » 06:54
01/06/20
01/06
06:54
01/06/20
06:54
LCI

Lannett

$8.48 /

-0.255 (-2.92%)

Lannett announced that it…

Lannett announced that it has commenced marketing Venlafaxine extended release, or ER, tablets, 150 mg and 225 mg, USP, and Lidocaine topical solution 4%. The estimated IQVIA market values of Venlafaxine ER tablets, 150 mg and 225 mg, USP, and Lidocaine topical solution 4% are approximately $150M and $17M, respectively, for the 12 months ending November 2019, although actual generic market values are expected to be lower.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Lannett receives FDA approvals for 2 dosage strengths of BAC Capsules » 06:53
12/23/19
12/23
06:53
12/23/19
06:53
LCI

Lannett

$9.13 /

-0.015 (-0.16%)

Lannett announced that it…

Lannett announced that it has received approvals from the FDA of its Abbreviated New Drug Applications, or ANDAs, for Butalbital, Acetaminophen and Caffeine, or BAC, Capsules, USP, 50mg/300mg/40mg and BAC Capsules, USP, 50 mg/325 mg/40 mg. The two dosage strengths of BAC Capsules, have a combined estimated IQVIA market value of approximately $68.6 million for the 12 months ending October 2019, although actual generic market values are expected to be lower.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Syndicate
Lannett files $50M mixed securities shelf  16:14
12/20/19
12/20
16:14
12/20/19
16:14
LCI

Lannett

$9.10 /

-0.045 (-0.49%)

 
ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Lannett to commence marketing for generic Adderall XR in coming months » 07:02
12/12/19
12/12
07:02
12/12/19
07:02
LCI

Lannett

$8.79 /

-0.085 (-0.96%)

Lannett announced that it…

Lannett announced that it expects to commence marketing in the coming months a generic version of Adderall XR, an extended-release mixed salt of a single entity Amphetamine tablet product with strengths of 5 mg, 10 mg, 15 mg, 20 mg, 25 mg and 30 mg tablets. Adderall XR including generic versions have an estimated IQVIA market value of approximately $1.3B for the 12 months ending October, although actual generic market values are expected to be lower. In March, Lannett entered into an agreement with Elite Pharmaceuticals and SunGen Pharma to be the exclusive U.S. distributor of certain drug products, including generic Adderall IR and generic Adderall XR. Under the agreement, Lannett primarily provides sales, marketing and distribution support for the products, for which it receives a share of the profits.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Lannett rises 8.3% » 09:47
12/04/19
12/04
09:47
12/04/19
09:47
LCI

Lannett

$9.58 /

+0.72 (+8.13%)

Lannett is up 8.3%, or…

Lannett is up 8.3%, or 74c to $9.60.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Fly Intel: Pre-market Movers » 09:03
12/04/19
12/04
09:03
12/04/19
09:03
GPRO

GoPro

$3.86 /

+0.025 (+0.65%)

, LCI

Lannett

$8.86 /

+0.1 (+1.14%)

, NTES

NetEase

$317.20 /

+3.53 (+1.13%)

, OMER

Omeros

$14.36 /

-0.11 (-0.76%)

, GIII

G-III Apparel

$28.48 /

-0.48 (-1.66%)

, WDAY

Workday

$173.52 /

+1.52 (+0.88%)

, ZS

Zscaler

$52.77 /

+1.69 (+3.31%)

, RVNC

Revance

$20.13 /

+0.13 (+0.65%)

, VRAY

ViewRay

$4.44 /

+1.04 (+30.59%)

HIGHER: Lannett (LCI), up…

HIGHER: Lannett (LCI), up 9% after announcing results from the first human study evaluating insulin glargine that Lannett is developing with its strategic alliance partners within the HEC Group of companies. The study met all primary endpoints... GoPro (GPRO), up 5% after reporting record sales from the Black Friday and Cyber Monday shopping period... NetEase (NTES), up 2% after Goldman Sachs analyst Bill Liu upgraded shares to Buy from Neutral with a price target of $368, up from $300... Omeros (OMER), up 9% after announcing data from its clinical trial of the company's investigational complement inhibitor narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. DOWN AFTER EARNINGS: G-III Apparel (GIII), down 8%... Workday (WDAY), down 4%... Zscaler (ZS), down 5%. ALSO LOWER: Revance (RVNC), down 17% after its 6.5M share spot secondary offering priced at $17.00 per share... ViewRay (VRAY), down 2% after its upsized 41.55M share secondary offering priced at $3.13 per share.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04
    Dec
  • 04
    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.